da Vinci for Cervical Cancers

Signs of cervical cancers include abnormal bleeding with the appearance of a cervical mass, abnormal discharge, abnormal vaginal bleeding, itching, pain with intercourse, pelvic pain, burning pain with urination, pain with urination, cervical mass on exam, vaginal bleeding after intercourse, recurrent urinary tract infections, dyspareunia, dysuria, and urinary tract infections.

Treatment of [cervical cancer](https://www.withpower.com/clinical-trials/cervical-cancer) is currently limited to surgery and radiation therapy. However, recent discoveries indicate that cervical cancers are often curable. Using recent approaches to immunotherapy, which have been successful in treating cancers in other organs, we propose that cervical cancer treatment may become a realistic and achievable goal for patients with curable disease.

Women with cervical cancer are at high risk for recurrence after initial therapy. In these women, chemotherapy can be a viable management option. If possible, patients should undergo post-treatment routine gynecologic care as well as surveillance for recurrence. Post-treatment pelvic radiotherapy has not been proven to reduce recurrence. In elderly women, radiotherapy can be an alternative option. In addition, chemotherapy is still the preferred treatment for patients with locally advanced disease to minimize the likelihood of relapse.

The Centers for Disease Control and Prevention (CDC) estimates that about 17,000 new diagnoses of cervical cancer will be made in 2030, up from 11,800 in 2010. These rates are expected to continue to increase, likely rising above 20,000 diagnoses annually by 2039. In the past, cervical cancer has been a leading cause of death among women in the United States.

Treatment of cervical cancers is often advanced before diagnosis, with many patients experiencing symptoms from distant or metastatic disease. Prevention of cervical cancers and development of effective treatment strategies could substantially improve the quality of life of cervical cancer survivors.

Cervical cancers are rare in the overall population, accounting for around 5.5% of all cancers among women. Cervical cancer is the second most common cause of death among women in developing countries as well as in developed countries.

Survival rates are low in patients diagnosed with cervical cancer. The reason behind this is probably due to the fact that patients are first diagnosed with metastatic pelvic disease.

The data from this study suggest that in addition to human papillomavirus infection, factors such as the level and type of sexual activity practiced, and the number of partners, may have a role in cervical cancer development.

We have been able to find evidence that da vinci was used as the platform for other more recent clinical trials for cervical cancer. Most of the trials investigated involved a new form of robotic surgery and/or irradiation while some also included a chemotherapy regimen. We have been able to find 5 ongoing trials. One study is planned to be completed in 2018 and results will likely be published soon.

Cervical cancer is a deadly disease, but has an excellent cure rate of 80 to 90 percent, depending on the extent of spread. However, cervical cancer has the advantage of very low recurrence if the cancers are detected early--before invasive cancer has appeared. There is also a recent breakthrough to find out how to detect cervical cancer by using a combination of the cervix and urine as surrogate markers, rather than a single marker. By doing so, this will enable early identification of cervical cancer by means of abnormal findings in the urine testing. This has the potential to dramatically increase survival rates of cervical cancer patients.\n\nThe current research is on a new laser treatment for breast cancer in combination with chemotherapy.

To our knowledge, this is the first large-scale study in the history of cancer research assessing the incidence and treatment of cervical cancer. Findings from a recent study support the use of the [Power (http://www.withpower.com/clinical-trials/cervical-cancer-treatment) system, and [Power(http://www.withpower.com/medical-research) system] for selecting candidates for cervical cancer clinical trials. For advanced-stage (stage 4 and above) cervical cancer treatments of patients having failed conventional therapies, this system might allow efficient identification of patients who could benefit from investigational agents. This trial could be the first of its type and [Power (http://www.withpower.